Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/inaugural-lecture-of-li-shu-fan-medical-foundation-professorship-in-clinical-oncology-by-prof-tony-mok-declaration-of-war-against-lung-cancer
https://www.med.cuhk.edu.hk/press-releases/inaugural-lecture-of-li-shu-fan-medical-foundation-professorship-in-clinical-oncology-by-prof-tony-mok-declaration-of-war-against-lung-cancer

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Prof. Tony S.K. Mok, Professor in Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK), delivered his inaugural lecture today (11 March) as Li Shu Fan Medical Foundation Professor of Clinical Oncology titled ‘Declaration of War Against Lung Cancer’.

 

Fighting cancer is like fighting a war.  Unfortunately we have been losing the battle against lung cancer for many years. Global casualties from lung cancer amounted to1 million in 2011. Only in recent years, with the development of molecular targeted therapy, have we begun to gain some ground in this tough fight.  In the lecture, Prof. Tony Mok expounded the mechanism of molecular targeted therapy, which can be used to target the tumor by understanding the molecular profile of each individual lung cancer.  In future, Professor Mok hopes to optimize treatment for patients with known driver oncogene by sophisticated detection, strategy on combination therapy and combating resistance.

 

Professor Mok also urged doctors, patients, families, advocates, researchers, pharmaceutical companies and governments to join hands and develop novel strategies in research and care delivery. He believed that only with such an effort will we eventually be the victors in this war against lung cancer.

 

Prof. Tony S.K. Mok was trained at the University of Alberta and subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Canada. He returned to Hong Kong in 1996 to pursue an academic career. He is now a Professor in the Department of Clinical Oncology at CUHK.

 

His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IRESSA Pan-Asia Study (IPASS), a landmark study that established the role of first-line gefitinib in patients with EGFR mutation.

 

He is active and experienced in serving academic societies. He is President of the International Association for the Study of Lung Cancer (IASLC), Former Chair of the American Society of Clinical Oncology (ASCO) International Affairs Committee, Chairman of the Hong Kong Cancer Therapy Society and Vice President of the Chinese Society of Clinical Oncology (CSCO). He is closely affiliated with the oncology community in China, and has received an Honorary Professorship at Guangdong Province People’s Hospital, a Guest Professorship at Peking University School of Oncology and a Visiting Professorship at Shanghai Jiao Tong University. Professor Mok is the recipient of the 2013 Addario Lectureship Award bestowed by The Bonnie J Addario Lung Cancer Foundation at the 14th International Lung Cancer Congress, in recognition of his pioneering efforts in lung cancer research to combat cancer.

 

Professor Mok has contributed to over 180 articles in international peer review journals, including The New England Journal of Medicine, Science, Lancet and Journal of Clinical Oncology, and contributed to multiple editorials and textbooks. He is an Associate Editor of Journal of Clinical Oncology and Asia Pacific Journal of Clinical Oncology. He has also authored six books in Chinese and hosted three television series in Hong Kong.

 

About Li Shu Fan Medical Foundation Professorship in Clinical Oncology

 

The Li Shu Fan Medical Foundation established two Li Shu Fan Medical Foundation Professorships in Clinical Oncology at the CUHK Faculty of Medicine in February 2013 and February 2014 in support of academic research in clinical oncology and in memory of the late Dr. Li Shu Fan.  Each professorship lasts for a period of ten years. The incumbents of the Professorship are Prof. Anthony Chan Tak-cheung and Prof. Tony Mok from the Department of Clinical Oncology at CUHK.

 

 

For more photos, please visit:
http://www.cpr.cuhk.edu.hk/en/events_recap_detail.php?id=167&s=

 

Prof. Tony Mok delivers his inaugural lecture

Prof. Tony Mok delivers his inaugural lecture as Li Shu Fan Medical Foundation Professor of Clinical Oncology.

Prof. Francis Chan, Dean of Medicine, CUHK; Dr Ko Wing-man, Secretary for Food and Health, HKSAR

(From left) Prof. Francis Chan, Dean of Medicine, CUHK; Dr Ko Wing-man, Secretary for Food and Health, HKSAR; Prof. Tony Mok, Li Shu Fan Professor of Clinical Oncology, CUHK; Dr. Walton Li, Chairman, Board of Governors, Li Shu Fan Medical Foundation; and Prof. Joseph Sung, Vice-Chancellor, CUHK.

Prof. Joseph Sung presents a certificate of appreciation to Dr. Walton Li.

Prof. Joseph Sung (left) presents a certificate of appreciation to Dr. Walton Li.

A group photo of CUHK members and representatives of Hong Kong Sanatorium & Hospital.

A group photo of CUHK members and representatives of Hong Kong Sanatorium & Hospital.

temp 

More Press Releases

International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

Research
CUHK co-leads global lung cancer study  Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

CUHK co-leads global lung cancer study Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

Research
CU Medicine collaborates with South Korean institutes to develop  an AI-powered analytic tool for lung cancer immunotherapy

CU Medicine collaborates with South Korean institutes to develop an AI-powered analytic tool for lung cancer immunotherapy

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
CUHK discovers a blood regulator linked to tumour microenvironment formation,  sparking a new therapeutic target for lung cancer

CUHK discovers a blood regulator linked to tumour microenvironment formation, sparking a new therapeutic target for lung cancer

Research
International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

Research
 CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

Research
CUHK performs world’s first robotic-assisted bronchoscopic  microwave ablation of lung metastases

CUHK performs world’s first robotic-assisted bronchoscopic microwave ablation of lung metastases

Surgical advancement
CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

Surgical advancement
CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

Response
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.